Adverse events in patients with leprosy on treatment with thalidomide

AUTOR(ES)

Drummond, Paula Lana de Miranda

FONTE

Rev. Soc. Bras. Med. Trop.

DATA DE PUBLICAÇÃO

11/04/2019

RESUMO

Abstract INTRODUCTION: Thalidomide, used to treat erythema nodosum leprosum (ENL), is associated with severe adverse events (AEs) and is highly teratogenic. METHODS: A cross-sectional study was conducted on thalidomide-treated patients with ENL. AEs and selected variables were investigated through interviews and assessment of medical records. Odds ratios with 95% confidence intervals were estimated via logistic regression. RESULTS: Peripheral neuropathy symptoms and deep vein thrombosis (DVT) were the most common AEs reported. Although women of reproductive age used contraceptives, <50% of patients reported using condoms. Polypharmacy was associated with all endpoints, except DVT. CONCLUSIONS: Pharmacovigilance is crucial to prevent harmful thalidomide-associated AEs.

Documentos Relacionados

• Anti-phospholipid syndrome in seven leprosy patients with thrombotic events on corticosteroid and/or thalidomide regimen: insights on genetic and laboratory profiles
• Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients
• Aphthous ulcers in HIV-infected patients: treatment with thalidomide.
• The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada
• Adverse events with Zyban (buproprion)